Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Imbria extends Series B financing with new investor AXA IM Alts to advance ninerafaxstat and address urgent global cardiovascular health challenges.
-
Prof Lemmens underscores large unmet medical need in intracerebral hemorrhage “Very encouraging” data from Phase 2a trial with lead asset BIOX-101 Bioxodes is preparing for a possibly registrational...
-
Imbria Pharmaceuticals announces first patient randomized in Phase 2b FORTITUDE-HCM trial of ninerafaxstat for non-obstructive hypertrophic cardiomyopathy.
-
Smart Health Diagnostics Company Appoints Sarah Barry as Lead Controller to Oversee Finance Operations in Commercial Stage
-
Imbria partners with HCMA to boost FORTITUDE-HCM trial enrollment of ninerafaxstat, a novel therapy for patients with non-obstructive HCM.
-
Ancien dirigeant de GSK et de Sanofi, M. Monteyne a supervisé le développement de Cervarix® et permis l’avancement de plusieurs traitements pionniers dans les maladies rares ; il apporte dix années...
-
Former GSK and Sanofi executive, led Cervarix® development and advanced pioneering therapies for rare diseases, decade of experience as venture capitalistStrengthens Bioxodes leadership following...
-
Austin, TX, USA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Virtual Clinical Trials Market Size, Trends and Insights By Study Design...
-
Austin, TX, USA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Left Ventricular Assist Devices Market Size, Trends and Insights By Product...
-
Imbria Pharmaceuticals Strengthens Leadership, Appoints Dr. Cheruvu as Board Chair; James Januzzi, MD, as Senior Research Advisor and SAB Chair.